Recombinant Protein Drugs
Therapeutic proteins produced by engineered cells, including recombinant hormones, enzymes, cytokines, and clotting factors.
Core metadata
- ID: recombinant_protein_drugs
- Era: Modern
- First known date: 1982 (exact)
- Region: United States, Europe, and global biopharmaceutical manufacturing
- Review status: source_checked
- Maturity: established
Prerequisites
- Cell Culture (cell_culture)
- Good Manufacturing Practice (good_manufacturing_practice)
- Recombinant DNA & Genetic Engineering (recombinant_dna_genetic_engineering)
Dependents
Fields
Field lanes
- Pharmaceuticals & Drug Development: Biologics & Vaccines
Node sources
- Recombinant DNA Technology (National Human Genome Research Institute, 2026, official_agency) • Supports: node, maturity
- Biologics (U.S. Food and Drug Administration, 2026, official_agency) • Supports: node, maturity
Prerequisite edge evidence
Edge/source evidence summary:
- Prerequisite edges: 3
- Average edge confidence: 81%
- Prerequisite sources: 3
- expert_inference: 3
| Prerequisite | Type | Confidence | Evidence level | Note | Sources |
|---|---|---|---|---|---|
| Recombinant DNA & Genetic Engineering (recombinant_dna_genetic_engineering) | required | 90% | expert_inference | Recombinant protein drugs require engineered DNA constructs to express therapeutic proteins in host cells. |
|
| Cell Culture (cell_culture) | required | 84% | expert_inference | Therapeutic protein production depends on controlled growth of microbial or mammalian cells for expression and scale-up. |
|
| Good Manufacturing Practice (good_manufacturing_practice) | enabling | 68% | expert_inference | Good Manufacturing Practice provides a capability that enables this technology without being the only possible path. |
|
This page is generated from canonical era JSON and is indexable by URL.